SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Press release - No. 07 / 2018
Zealand Pharma to present at the Needham Healthcare Conference, March 27, 2018 in New York
Copenhagen, March 22, 2018 - Britt Meelby Jensen, President and Chief Executive Officer (CEO) of Zealand Pharma, will present at the 17th Annual Needham Healthcare Conference in New York, at the Westin Grand Central Hotel on Tuesday, March 27, 2018 at 10:00-10:30 am (EST).
For further information, please contact:
Britt Meelby Jensen, President and Chief Executive Officer
Tel: +45 51 67 61 28, e-mail: [email protected]
Mats Blom, Senior Vice President, Chief Financial Officer
Tel: +45 31 53 79 73, e-mail: [email protected]
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim, and a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.
Attachment:
http://www.globenewswire.com/NewsRoom/AttachmentNg/c2e28375-1185-4700-86f8-502d97a8bbe9
